CytomX Therapeutics develops Probody⢠therapeutics for the treatment of cancer. Probody therapeutics are fully recombinant masked antibodies that are designed to remain inert in healthy tissue but become activated specifically in the tumor microenvironment. The Probody approach is designed to blunt systemic toxicities associated with antibodies and expand the therapeutic window of these drugs, potentially unlocking new therapeutic targets. The Company is initially focusing this highly innovative platform to discover and develop new immunotherapy and antibody drug conjugate therapies to treat areas of major unmet medical need in oncology. Source
No articles found.
Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical compan...
Spero Therapeutics, Inc. is a multi-asset, clin...
Aileron Therapeutics is a clinical stage company discovering and developing novel ...
Aileron Therapeutics is a clinical stage compan...
Integra LifeSciences, a world leader in medical devices, is dedicated to limiting ...
Integra LifeSciences, a world leader in medical...
Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused o...
Mirum Pharmaceuticals Inc. is a clinical-stage ...
At Sesen Bio, we are committed to renewing life for people with cancer. We are a l...
At Sesen Bio, we are committed to renewing life...
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on develop...
Cara Therapeutics is a clinical-stage biopharma...
VBL Therapeutics is a publicly traded (NASDAQ: VBLT), late-stage clinical biopharm...
VBL Therapeutics is a publicly traded (NASDAQ: ...
Join the National Investor Network and get the latest information with your interests in mind.